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OBJECTIVE—To assess whether recently discovered genetic
loci associated with hyperglycemia also predict long-term
changes in glycemic traits.
RESEARCH DESIGN AND METHODS—Sixteen fasting glu-
cose-raising loci were genotyped in middle-aged adults from the
Gene x Lifestyle interactions And Complex traits Involved in
Elevated disease Risk (GLACIER) Study, a population-based
prospective cohort study from northern Sweden. Genotypes
were tested for association with baseline fasting and 2-h post-
challenge glycemia (N  16,330), and for changes in these
glycemic traits during a 10-year follow-up period (N  4,059).
RESULTS—Cross-sectional directionally consistent replication
with fasting glucose concentrations was achieved for 12 of 16
variants; 10 variants were also associated with impaired fasting
glucose (IFG) and 7 were independently associated with 2-h
postchallenge glucose concentrations. In prospective analyses,
the effect alleles at four loci (GCK rs4607517, ADRA2A
rs10885122, DGKB-TMEM195 rs2191349, and G6PC2 rs560887)
were nominally associated with worsening fasting glucose con-
centrations during 10-years of follow-up. MTNR1B rs10830963,
which was predictive of elevated fasting glucose concentrations
in cross-sectional analyses, was associated with a protective
effect on postchallenge glucose concentrations during follow-up;
however, this was only when baseline fasting and 2-h glucoses
were adjusted for. An additive effect of multiple risk alleles on
glycemic traits was observed: a weighted genetic risk score (80th
vs. 20th centiles) was associated with a 0.16 mmol/l (P  2.4 
10
6) greater elevation in fasting glucose and a 64% (95% CI:
33–201%) higher risk of developing IFG during 10 years of
follow-up.
CONCLUSIONS—Our ﬁndings imply that genetic proﬁling
might facilitate the early detection of persons who are genetically
susceptible to deteriorating glucose control; studies of incident
type 2 diabetes and discrete cardiovascular end points will help
establish whether the magnitude of these changes is clinically
relevant. Diabetes 60:345–354, 2011
G
lucose homeostasis in healthy individuals is
tightly controlled through a complex pathway
of regulatory mechanisms involving multiple
organs and tissues. Chronic elevations in fast-
ing and postchallenge blood glucose concentrations are
the cardinal feature of type 2 diabetes. Type 2 diabetes and
nondiabetic variations in fasting and postchallenge glu-
cose levels are highly heritable (1,2); in recent years, the
identities of several loci underpinning these heritability
estimates have been revealed (3,4). Because a person’s
genotype remains unchanged throughout life, variants that
predict deterioration in glucose levels later in life might be
used to identify susceptible individuals for early interven-
tion long before changes in glucose concentrations are
visible.
Although the cross-sectional relationships between mul-
tiple fasting (3) and postchallenge (3,4) glucose-raising
loci recently have been conﬁrmed in large cohort collec-
tions, it is unclear whether these loci predict long-term
deteriorations in glucose homeostasis. Several cross-sec-
tional studies in European whites or Chinese Han have
identiﬁed variants within or near one of seven genes
(TCF7L2, MTNRIB, GCK, GCKR, G6PC2, DGKB-
TMEM195, and SLC30A8) that raise fasting glucose con-
centrations and/or risk of impaired fasting glucose (IFG)
(5–17). In the most recent large-scale effort to discover
new fasting glucose–related loci, the Meta-Analyses of
Glucose and Insulin-Related Traits Consortium (MAGIC)
investigators identiﬁed a further nine predisposing loci
in European whites: rs11708067 (ADCY5), rs7944584
(MADD), rs10885122 (ADRA2A), rs174550 (FADS1),
rs11605924 (CRY2), rs11920090 (SLC2A2), rs7034200
(GLIS3), rs340874 (PROX1), and rs11071657 (C2CD4B).
To our knowledge, the existing longitudinal epidemiologic
studies in which genetic predictors of change in fasting
glucose concentrations have been examined have focused
on variants in TCF7L2 (5,18,19), and no longitudinal
studies before the present one have examined the entire
array of conﬁrmed fasting glucose-raising loci. The extent
to which the accumulation of risk alleles inﬂuences fasting
and postchallenge glucose levels is also unclear.
The purpose of the present study was to examine the
cross-sectional and longitudinal relationships between
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gly and in combination, with fasting and postchallenge
glucose concentrations in the Gene x Lifestyle interactions
And Complex traits Involved in Elevated disease Risk
(GLACIER) Study, a population-based prospective cohort
study of adults from northern Sweden.
RESEARCH DESIGN AND METHODS
The GLACIER Study is a prospective, population-based cohort study compris-
ing 19,547 adults from the northern Swedish county of Va ¨sterbotten, nested
within the Northern Sweden Health and Disease Study (20). Participants were
excluded from the current analyses if they reported a physician diagnosis of
diabetes at baseline or follow-up, had measured glucose concentrations below
1 mmol/l or above the World Health Organization diagnostic thresholds for
type 2 diabetes (21), or if 50% of the fasting glucose genotypes were missing.
Thus, the maximum number of individuals included in the baseline analyses
ranged from 15,483 (for 2-h glucose models) to 16,330 (for fasting glucose
models). All GLACIER participants underwent detailed health and lifestyle
examinations as part of the Va ¨sterbotten Intervention Programme, an ongoing
population-based prospective cohort study focused on type 2 diabetes,
cardiovascular disease, and common cancers (20,22). Since 1985, all residents
of the county of Va ¨sterbotten have been invited to visit their primary care
center for a clinical examination in the year of their 40th, 50th, and/or 60th
birthday. The protocol is standardized across study centers and conducted by
trained research nurses. Baseline examinations for GLACIER participants
were undertaken from 1985 through 2004. Of the 16,330 participants free from
diabetes and other major chronic diseases at baseline, 4,059 had undergone a
10-year follow-up examination between January 1995 and December 2007 and
were included in the longitudinal analyses. The follow-up examination was
identical to the baseline examination with the exceptions that waist circum-
ference was measured and modiﬁcations had been made to questionnaires on
diet and physical activity. All participants gave written informed consent and
the Regional Ethical Review Board in Umeå approved all aspects of the study.
Clinical measures. The clinical methods have been described in detail
previously (20,22). Brieﬂy, weight (to the nearest 0.1 kg) and height (to the
nearest 1 cm) were measured with a calibrated balance-beam scale and a
wall-mounted stadiometer, respectively, with participants wearing indoor
clothing without shoes. BMI was calculated as weight in kilograms divided by
height in meters squared (kg/m
2). Systolic and diastolic blood pressures were
measured once, after a 5-min rest, using a mercury-gauge sphygmomanometer
with the participant in a supine position. Capillary blood was drawn after an
overnight fast, and a second sample was drawn 2 h after a standard 75-g oral
glucose load (21). Capillary plasma glucose concentrations were measured
with a Reﬂotron bench-top analyzer (Roche Diagnostics Scandinavia AB).
Before the ﬁrst blood draw, 86% of the cohort had fasted for a minimum of 8 h,
3% had fasted for between 4 and 8 h, and data were missing for 11%.
Sensitivity analyses (associations of single nucleotide polymorphisms [SNPs]
with glucose levels) that included all individuals versus only those who had
fasted 8 h did not yield materially different results. However, to control for
any residual effect that fasting time might have, a variable for fasting time was
included in the analyses (8 h vs. 4–8 h vs. unknown fasting duration).
SNP selection and genotyping. Fasting glucose SNPs were identiﬁed
through participation in the MAGIC (3). The GLACIER Study was not included
in the original MAGIC paper (3). DNA was extracted from peripheral white
blood cells (23,24) and genomic DNA samples were diluted to 4 ng/l.
Genotyping was performed using the OpenArray SNP Genotyping System
(BioTrove, Woburn, MA). One in 10 GLACIER samples was genotyped in
duplicate, in which genotyping concordance was 99%. The genotype success
rate was 96% for all SNPs and no departures from Hardy-Weinberg equilib-
rium were observed (P  0.001).
Genetic risk score. The effect of multiple genetic risk loci on the glycemic
traits was studied by constructing two different types of genetic risk score
(GRS) for each study participant. The ﬁrst assumed an equal magnitude of
effect for each risk allele and was generated for each participant by summing
the number of risk alleles at each of the 16 SNP loci. Thus, because these are
all biallelic loci, the GRS has a maximum possible value of 32 and a minimum
possible value of 0. To calculate the second GRS, we used published effect
sizes for each SNP (3) to weight the contribution of each risk allele. The
weighted alleles were subsequently summed into a single score (wGRS). The
maximum value for the wGRS for fasting and postchallenge glucoses are 0.948
and 1.548, respectively (i.e., 32 risk alleles  the relevant  coefﬁcient for each
allele). To facilitate the interpretation of the results, each individual’s wGRS
was divided by the maximum possible wGRS and multiplied by 32 (the
maximal number of risk alleles) (25). The purpose of undertaking this last step
is to create a variable which is expressed on the same scale as the unweighted
GRS, thus facilitating comparisons between these two scores. Missing geno-
types were imputed as previously described (26) by replacing each missing
genotype with its mean value, which was derived from the fraction of the
cohort in which the genotype data were available. Analyses were performed
using the wGRS on the continuous scale and on a categorical scale (wGRS
quintiles). We used the latter to compare the magnitude of the effects between
the top and bottom quintiles of the wGRS. The purpose of this comparison is
to illustrate the extent to which having a relatively high genetic burden (i.e.,
80% of the wGRS distribution) verses a relatively low genetic burden (i.e.,
20% of the wGRS distribution) inﬂuences glucose homeostasis. The cut
points were chosen because they allow for the comparison of effects for
genetically distinct subgroups of the population, while ensuring these sub-
groups are sufﬁciently prevalent to be reasonably generalizable. There was no
biologically informed reason for choosing these cut points as the relationship
of the wGRS with glucose levels is linear (as illustrated in Fig. 1).
Nongenetic risk score. Two nongenetic risk scores (NGRSs) were computed
and used to predict the development of IFG. The ﬁrst score was comprised of
baseline age, sex, and family history of type 2 diabetes (NGRS_1). The second
score, which was similar in design to the Framingham risk score (27),
included these three variables in addition to baseline fasting and 2-h glucose
concentrations, triglycerides, diastolic and systolic blood pressures, and BMI
(NGRS_2). The ability to predict IFG for both scores was compared with the
predictive accuracy of a genetic model including all 16 fasting glucose loci and
15 additional conﬁrmed type 2 diabetes loci (CDKN2A/B rs10811661; HNF1B
rs4430796; PPARG rs1801282; WFS1 rs10010131; ADAMTS9 rs4607103; CD-
KAL1 rs7754840; CAMK1D rs12779790; NOTCH2 rs10923931; KCNJ11 rs5912;
THADA rs7578597; IGFBP2 rs4402960; JAZF1 rs864745; HHEX rs1111875;
KCNQ1 rs2237895; TSPAN8 rs7961581).
Statistical analysis. All analyses were undertaken using SAS software
(version 9.1, SAS Institute, Cary, NC). A 	
2-test with one degree of freedom
was used to determine Hardy-Weinberg equilibrium. A two-sided paired-
samples t test was used to compare mean values at baseline and follow-up.
Dependence of the variables was assessed with the Pearson correlation
coefﬁcient. Generalized linear models were used to test cross-sectional
associations between each variant and fasting or 2-h glucose concentrations.
Associations with changes in fasting and 2-h postchallenge glycemia over the
10-year follow-up period were assessed in two ways: 1) follow-up glucose
(fasting or 2-h) included as the dependent variable and the respective baseline
glucose variable as a covariate; 2) 
 glucose (i.e., the difference between
follow-up and the baseline fasting or 2-h glucose concentrations) included as
the dependent variable and the respective baseline glucose trait as a covariate.
Model 2 yields more easily interpretable coefﬁcients than model 1, but
potentially overadjusts for baseline glucose levels, given that this trait is
included both in the calculation of the 
 and as a covariate in the regression
model; for these reasons, model 2 was used only to graphically illustrate the
results (Fig. 1). Logistic regression was used to assess the association
between each variant and IFG deﬁned as fasting plasma glucose concentra-
tions 5.6 mmol/l and 7.0 mmol/l according to the ADA guidelines (28). All
models were adjusted for age, sex, and fasting time, and additional adjust-
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FIG. 1. Association between the weighted genetic risk score and change
in fasting glucose concentrations during 10 years of follow-up. The
weighted genetic risk score (wGRS) was constructed as described in
the RESEARCH DESIGN AND METHODS section. Data are mean (95% CI). 
glucose levels (follow-up minus baseline) per quintile of the wGRS are
adjusted for baseline age, sex, baseline fasting glucose, fasting time at
baseline and follow-up, and follow-up time (N  4,059).
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Dupuis et al. (3), all models assumed an additive mode of inheritance. The 
inﬂation, owing to multiple hypothesis testing, was controlled for using
Holm’s procedure (29). The relative predictive accuracy of the genetic and
nongenetic risk scores was determined using the area under the receiver
operator characteristic curves (ROC AUC) (30). P  0.05 was considered
statistically signiﬁcant.
RESULTS
Table 1 reports baseline characteristics for the 16,330
participants in the full GLACIER cohort. The correlation
between fasting and 2-h glucose concentrations at baseline
was r  0.25 (P  0.0001). The baseline and follow-up
characteristics are shown in Table 2 (n  4,059). Mean
( SD) follow-up duration was 9.9  0.3 years and ranged
from 6 to 13 years. On average, the level of all quantitative
variables shown in Table 2 increased signiﬁcantly between
baseline and follow-up (P  0.0001).
Replication of genetic associations with fasting and
postchallenge glycemia
Baseline fasting glucose concentrations. Table 3 sum-
marizes associations between each of the 16 fasting glu-
cose-raising loci and fasting glycemia after adjustment
for age, sex, and fasting time: 12 of the SNPs (MTNR1B
rs10830963, G6PC2 rs560887, GCK rs4607517, CRY2
rs11605924, DGKB-TMEM195 rs2191349, SLC30A8
rs13266634, GCKR rs780094, TCF7L2 rs7903146, ADRA2A
rs10885122, FADS1 rs174550, SLC2A2 rs11920090, and
PROX1 rs340874) were statistically associated with fasting
glucose concentrations. The effect estimates from these
models are directionally consistent with the original report
(3), irrespective of statistical signiﬁcance. Further adjust-
ment for BMI made no material difference to these results
(data not shown).
Baseline 2-h glucose concentrations. As shown in
Table 3, 8 of the 16 fasting glucose-raising SNPs were
associated with 2-h glucose concentrations in models
adjusted for age, sex, and fasting time. The associations
for ﬁve of the SNPs (ADCY5 rs11708067, TCF7L2
rs7903146, GCK rs4607517, SLC30A8 rs13266634, and
C2CD4B rs11071657) were consistent with the original
ﬁndings of Dupuis et al. (3). The previously reported
associations for MTNR1B rs10830963, GCKR rs780094,
and GLIS3 rs7034200 failed to replicate in the GLACIER
study cohort, but were directionally consistent with the
original report. By contrast to the original report, CRY2
rs11605924, FADS1 rs174550, and SLC2A2 rs11920090
were signiﬁcantly associated with 2-h glucose concentra-
tions in the GLACIER cohort (Table 3).
Although ﬂuctuations in postabsorptive glucose concen-
trations are primarily determined by the rate of peripheral
glucose disposal, the point from which postabsorptive
glucose concentrations begin to vary is set by the fasting
concentration. Thus, it is possible that associations be-
tween fasting glucose-raising loci and 2-h glucose concen-
trations might be observed purely because of their
correlation with fasting glucose concentrations. Accord-
ingly, we tested a secondary model that was additionally
adjusted for fasting glucose concentrations. As hypothe-
sized, these models generally yielded weaker associations
between the selected loci and 2-h glucose concentrations
(Table 3); the nominal associations observed for SLC30A8
rs13266634, SLC2A2 rs11920090, and FADS1 rs174550
were rendered nonsigniﬁcant. However, the strength of
the associations for C2CD4B rs11071657, MTNR1B
rs10830963, and GCKR rs780094 were all strengthened
with adjustment for fasting glucose (P  0.05, Table 3).
Adjusting the models for BMI did not materially affect the
results (data not shown).
Prospective analyses for fasting and postchallenge
glycemia. To examine the extent to which fasting glucose-
raising loci predict longitudinal changes in glucose ho-
meostasis, we modeled the effects of the 16 SNPs on
changes in fasting and 2-h glucose concentrations or the
development of IFG during 10 years of follow-up.
TABLE 1
Participant characteristics for the GLACIER Study cohort
(n  16,330)
Variable Mean or n* S Do r% *
Sex (male/female)* 6,526/9,872 40/60
Age (years) 52.3 8.8
BMI (kg/m
2) 25.9 4.1
Fasting glucose (mmol/l) 5.4 0.6
2-h glucose (mmol/l)† 6.7 1.5
NFG vs. IFG* 10,766/5,564 66/34
*Values are n and proportion (%). †2-h glucose concentrations
available for 15,828 participants. NFG, normal fasting glucose.
TABLE 2
Characteristics for GLACIER Study participants in whom baseline and 10-year follow-up exams were performed (n  4,059)
Variable
Baseline Follow-up
Mean or n SD or % Mean or n SD or %
Sex (male/female)* 1,479/2,580 36/64 — —
Age (years) 45.2 6.7 55.2 6.7
Family history of T2D*† 697/3,321/41 17/82/1 925/2,980/154 23/73/4
BMI (kg/m
2)‡ 25.1 3.7 26.2 4.0
Fasting glucose (mmol/l)‡ 5.3 0.6 5.5 0.7
2-h glucose (mmol/l)‡§ 6.5 1.3 7.1 1.7
Systolic blood pressure (mmHg)‡ 124 16 130 18
Diastolic blood pressure (mmHg)‡ 78 10 78 10
Triglycerides (mmol/l)‡¶ 1.3 0.8 1.4 0.9
NFG vs. IFG*# 3,087/964 76/24 2,073/1,953 51/49
*Values are n and proportion (%). †Yes/no/missing information. ‡A paired samples t test was used to compare mean values at baseline and
follow-up, all of which (except DBP) increased signiﬁcantly (P  0.0001). Follow-up duration averaged 9.9  0.3 years and ranged from 6
to 13 years. §2-h glucose available for 4,059 participants at follow-up. ¶Triglycerides available in 3,352 and 4,020 participants at baseline and
follow-up, respectively. #The number of individuals with IFG increased signiﬁcantly at follow-up compared with baseline (P  0.0001).
Frequencies were compared between baseline and follow-up using the Mantel-Haenszel 	
2 test (1 degree of freedom). T2D, type 2 diabetes;
NFG, normal fasting glucose.
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centrations. In models adjusted for baseline age, sex,
fasting glucose, fasting time, and follow-up time, the effect
alleles at the GCK rs4607517, ADRA2A rs10885122, DGKB-
TMEM195 rs2191349, and G6PC2 rs560887 loci were nom-
inally statistically associated with a greater elevation in
fasting glucose concentrations at follow-up (Table 4).
None of the SNPs remained statistically associated with
change in fasting glucose after correction for multiple
hypothesis testing (Table 4). Additionally adjusting the
models for BMI did not materially alter these results (data
not shown).
Prospective associations with 2-h glucose concen-
trations. After adjustment for baseline age, sex, baseline
2-h glucose, fasting time, and follow-up time, MTNR1B
rs10830963 and ADCY5 rs11708067 were associated with
change in 2-h glucose concentrations at a nominal level of
statistical signiﬁcance; neither ﬁnding remained signiﬁcant
after correction for multiple testing (Table 4).
Additionally adjusting the models for baseline and fol-
low-up fasting glucose concentrations strengthened the
association with change in 2-h glucose concentrations
observed for MTNR1B rs10830963 and the result remained
statistically signiﬁcant after correcting for multiple testing
(Pcorrected  0.0065, Table 4). Adjusting the analyses for
fasting glucose concentrations did not inﬂuence the
strength or magnitude of the association for ADCY5
rs11708067 and rendered the association for MADD
rs7944584 with change in 2-h glucose concentrations nom-
inally statistically signiﬁcant. With the exception of the
ﬁnding for MTNR1B rs10830963, none of these results
remained statistically signiﬁcantly after correcting for
multiple hypothesis testing (Table 4). None of the other
fasting glucose-raising SNPs was signiﬁcantly associated
with change in 2-h glucose concentrations during follow-
up. Adding BMI as a covariate to the above analyses made
no material difference to the results (data not shown).
Cumulative effects of the 16 fasting glucose-raising
loci on glucose homeostasis. To examine the cumulative
effects of the risk alleles on glucose homeostasis, we
tested models incorporating all loci into a single GRS.
wGRS on fasting and 2-h glucose concentrations.
Each additional unit of the wGRS (mean  17; range 
7–29 risk alleles) was associated with a 0.030 mmol/l (P 
1.3  10
75) higher fasting glucose concentration; individ-
uals 80th wGRS centile had on average 0.26 mmol/l (CI:
0.23–0.29) higher fasting glucose concentrations than
those individuals 20th centile. Adjusting for BMI did not
affect the magnitude, but strengthened the statistical sig-
niﬁcance of the association (P  2.3  10
79).
Each additional unit (risk allele) of the 2-h glucose
wGRS was associated with 0.026 mmol/l higher 2-h glu-
cose concentrations (P  4.4  10
12). Including BMI as a
covariate in the model slightly reduced the strength and
magnitude of the association (0.019 mmol/l, (P 
1.5  10
7). Individuals 80th wGRS centile had 0.17
mmol/l (95% CI: 0.10–0.24) higher 2-h glucose concentra-
tions than those individuals 20th centile.
In the subcohort with repeated measures, each unit of
the fasting glucose wGRS (mean  17; range  8–27 risk
alleles) was associated with a 0.019 mmol/l (P  1.9 
10
7) greater elevation in fasting glucose concentrations
from baseline to follow-up. Correcting the analysis for BMI
did not materially inﬂuence the magnitude of the associa-
tion but strengthened its statistical signiﬁcance (0.020
mmol/l, P  4.5  10
8). For individuals with a wGRS
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tions during follow-up was 0.16 mmol/l greater than
for those below the 20th wGRS centile (P  2.4  10
6,
Fig. 1).
After correcting for fasting glycemia, no additive effect
on longitudinal change in 2-h glucose concentrations was
observed in the wGRS model ( 0.00012 mmol/l, P 
0.98).
The unweighted GRS models yielded similar results to
the wGRS models (data not shown).
Associations between fasting glucose-raising loci and
IFG. To place the associations reported above into a
clinical context, we examined the associations between
the genetic variants and IFG and compared the power of
genetic models to predict the development of IFG during
follow-up against nongenetic prediction models.
Baseline associations with prevalent IFG. To quan-
tify the magnitude of the association between each SNP
and IFG, we began by modeling SNP associations with
prevalent IFG. In models adjusted for age, sex, and fasting
time, 10 of the fasting glucose-raising loci (MTNR1B
rs10830963, G6PC2 rs560887, GCK rs4607517, ADRA2A
rs10885122, DGKB-TMEM195 rs2191349, TCF7L2
rs7903146, SLC30A8 rs13266634, CRY2 rs11605924, GCKR
rs780094, and GLIS3 rs7034200) were associated with
elevated IFG risk (Table 5).
Prospective associations with incident IFG. Table 5
shows summary results for associations between each of
the fasting glucose-raising loci and risk of developing IFG
during follow-up, adjusted for baseline age, sex, baseline
IFG/NGT, fasting time, and follow-up duration. The glu-
cose-raising alleles at MTNR1B rs10830963, G6PC2
rs560887, and PROX1 rs340874 were signiﬁcantly associ-
ated with an increased risk of developing IFG during
follow-up.
Cumulative effects of the 16 fasting glucose-raising
loci on prevalent and incident IFG. Each wGRS unit
was associated with a 10% (95% CI: 9–11%) increased risk
of IFG. For individuals with a wGRS above the 80th
centile, the risk of IFG was 2.2-fold higher (95% CI:
2.0–2.5) than for individuals with a wGRS below the 20th
centile.
In the subcohort with repeated measures, each addi-
tional wGRS unit (risk allele) was associated with a 6%
(95% CI: 4–9%) greater risk of developing IFG during
follow-up. Those above the 80th GRS centile were 64%
(95% CI: 33–201%) more likely to develop IFG than those
below the 20th centile. Comparable results were obtained
in models where the unweighted GRS was included as the
predictor variable (data not shown).
Adjusting the above models for BMI did not materially
affect these results (data not shown).
Comparison of the predictive accuracy of genetic and
nongenetic risk scores on incident IFG. Several re-
ceiver operating characteristic (ROC) models were com-
pared to estimate the ability of genetic and nongenetic
models to predict the development of IFG during a 10-year
period follow-up and to examine whether combining in-
formation from both models signiﬁcantly improved the
power to predict this outcome. The genetic models include
all 16 fasting glucose loci outlined above, in addition to 15
independent type 2 diabetes loci. The effect alleles for
each of these SNPs were coded in a manner that is
consistent with the MAGIC fasting glucose (3) meta-
analysis (for fasting glucose loci) or the Diabetes Genetics
Replication And Meta-analysis (DIAGRAM) Consortium
type 2 diabetes meta-analysis (for type 2 diabetes loci)
(31). All models were adjusted for fasting time. NGRS_1
and NGRS_2 had ROC AUCs of 0.5796 (P  1.0  10
20)
and 0.6536 (P  1.0  10
20), respectively. The ROC AUC
for the genetic model was 0.5933 (P  1.0  10
20). The
predictive accuracy of the genetic model exceeded
NGRS_1 (P  0.033), but was less than NGRS_2 (P  1.7 
10
6). Adding the genetic information to NGRS_1 and
NGRS_2 signiﬁcantly improved the predictive accuracy of
both models (ROC AUCs from 0.5796 to 0.6133; P  1.45 
10
8 and 0.6536 to 0.6677, respectively; P  1.7  10
6).
Adjusting the models for the amount of time spent fasting
slightly inﬂated the ROC AUCs (supplementary Table 1
in the online appendix available at http://diabetes.
TABLE 5
Cross-sectional and longitudinal associations between each SNP and IFG
SNP
Nearest
gene(s)
Effect allele
(freq.)
Cross-sectional§ Longitudinal†
OR 95% CI OR 95% CI
rs10830963 MTNR1B G (0.28) 1.31 (1.24–1.38)* 1.17 (1.05–1.30)*
rs560887 G6PC2 C (0.71) 1.21 (1.15–1.28)* 1.13 (1.02–1.25)*
rs4607517 GCK A (0.15) 1.19 (1.11–1.27)* 1.13 (0.99–1.29)
rs10885122 ADRA2A G (0.89) 1.13 (1.05–1.22)* 1.16 (0.99–1.35)
rs2191349 DGKB-TMEM195 T (0.51) 1.11 (1.05–1.16)* 1.09 (0.99–1.20)
rs7903146 TCF7L2 T (0.20) 1.11 (1.05–1.18)* 1.08 (0.96–1.22)
rs13266634 SLC30A8 T (0.70) 1.10 (1.05–1.16)* 1.05 (0.95–1.17)
rs11605924 CRY2 A (0.50) 1.09 (1.04–1.14)* 1.09 (0.99–1.20)
rs780094 GCKR C (0.72) 1.08 (1.02–1.13)* 0.92 (0.83–1.02)
rs11920090 SLC2A2 T (0.86) 1.06 (0.99–1.13) 1.11 (0.96–1.28)
rs7034200 GLIS3 A (0.43) 1.05 (1.00–1.10)* 1.02 (0.93–1.12)
rs11708067 ADCY5 A (0.80) 1.05 (0.99–1.12) 0.99 (0.87–1.11)
rs340874 PROX1 C (0.53) 1.04 (0.99–1.09) 1.12 (1.02–1.24)*
rs174550 FADS1 T (0.66) 1.04 (0.98–1.09) 1.08 (0.97–1.19)
rs7944584 MADD A (0.76) 1.04 (0.98–1.10) 1.00 (0.89–1.12)
rs11071657 C2CD4B A (0.60) 1.01 (0.96–1.06) 1.02 (0.92–1.13)
Main effects are expressed as odds ratios (ORs) (IFG vs. normal glucose regulation) per copy of the effect allele at each locus ranked by effect
size on baseline association with IFG. §Models adjusted for age, sex, and fasting time (n  16,330). †Models adjusted for age and sex, fasting
times at baseline and follow-up, follow-up time, and baseline IFG (n  4,059). *P  0.05.
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in the model where the genetic information was added to
the NGRS_2, the ROC AUC did not materially differ (0.6621
vs. 0.6677) irrespective of whether fasting time was or was
not controlled for.
DISCUSSION
We sought to replicate and extend previously reported
associations between genetic loci and fasting and post-
challenge glucose concentrations (3) in the GLACIER
Study, an ethnically homogenous adult cohort from north-
ern Sweden. Twelve of 16 fasting glucose-raising loci were
statistically associated with fasting glycemia in a manner
that is directionally consistent with the original report (3).
Of the eight loci that were also found to be associated with
2-h postchallenge glycemia in the original report, ﬁve
replicated in the present study. After additionally adjusting
the analysis for the inﬂuence of fasting glycemia on 2-h
postchallenge glucose concentrations, six of the eight loci
replicated, and one novel association was observed (CRY2
rs11605924).
To our knowledge, no studies have yet reported on the
longitudinal relationships between all 16 fasting glucose-
raising loci recently reported by the MAGIC investigators
(3) and quantitative glycemic traits. Our analyses exam-
ined the predictive properties of the 16 gene variants
singularly and in combination during a decade of follow-
up. We found that four variants were nominally associated
with change in fasting glucose concentrations, but none
remained statistically associated after correction for mul-
tiple testing. The MTNR1B rs10830963 variant was associ-
ated with a protective effect on elevations in 2-h glucose
concentrations in our study. We also observed a strong
combined effect of the risk alleles on glucose concentra-
tions. For example, each wGRS count was associated with
a 0.019 mmol/l higher increase in fasting glucose concen-
tration and a 6% greater risk of developing IFG during a
decade of follow-up. When combined with other nonge-
netic risk factors, the gene variants signiﬁcantly improved
the predictive accuracy for incident IFG.
Four of the variants initially reported as predictive of
fasting glycemia (3) failed to replicate in the GLACIER
Study materials. These associations were, however, direc-
tionally consistent with the original report, but of 30 to 60%
lesser magnitude, suggesting that our study might have
been underpowered to detect these effects. Indeed, we
believe that the provision of conﬁdence intervals is far
more informative of whether a study is likely to be
underpowered to detect speciﬁc effects. Therefore, we
calculated the 95% CIs from the standard errors and
coefﬁcients provided in the original report from Dupuis et
al. (3) and compared these with the 95% conﬁdence
intervals derived from the GLACIER Study. This compar-
ison showed that the conﬁdence intervals from the two
studies are, without exception, heavily overlapping, mean-
ing that although the  coefﬁcients may appear to differ in
magnitude between studies, these differences are not
statistically signiﬁcant. Given these points, one cannot
discount the possibility that the failure to replicate some
SNP associations in the GLACIER Study is because of a
lack of statistical power.
Although sample size has a demonstrable impact on the
statistical power of a study, the linkage disequilibrium
structure of the population from which the GLACIER
Study emanates may also have affected the power to
detect previously reported effects. For example, as we
have previously shown (23,24,26), the minor allele fre-
quencies for SNPs associated with complex traits are often
lower in northern Swedish populations compared with
those in southern Sweden and central Europe. These
differences may be because of different founder effects in
combination with the low level of genetic admixture in
northern Sweden (32). It is possible that the lower minor
allele frequencies reﬂect different patterns of linkage dis-
equilibrium between the observed variants and the unob-
served causal variants, which, because of latent
misclassiﬁcation, might diminish power to detect associa-
tions between the observed variants and disease traits;
this may be the case for the rs7034200 (GLIS3)i nt h e
present report. Here, the minor allele frequency for the
rs7034200 variant is 43% in the GLACIER Study compared
with 49 and 54% reported in the MAGIC and HAPMAP CEU
collections, respectively.
In the cross-sectional analyses, three SNP associations
with 2-h glucose concentrations failed to replicate and
three novel SNP associations were observed. It is unclear
from their publication whether the 2-h glucose association
analyses reported by Dupuis et al. (3) included adjustment
for fasting glucose concentrations. Nevertheless, the asso-
ciation analyses reported here for 2-h glucose were highly
consistent with those reported by Dupuis et al. (3) when
fasting glucose was controlled for, with the majority of
these models being statistically signiﬁcant. We also iden-
tiﬁed one novel SNP association with 2-h glucose concen-
trations, which was for the CRY2 rs11605924 variant. It is
possible that with the low admixture rates and strong
founder effects evident in northern Sweden (32), these
ﬁndings may be population speciﬁc.
The protective effect on change in 2-h glucose concen-
trations observed for MTNR1B rs10830963 may be false
positive given the nominal level of statistical signiﬁcance
and the number of parallel hypotheses tested. However,
the magnitude of the inverse associations for MTNR1B
and 2-h glucose was similar in the full baseline GLACIER
cohort and in the repeated measures subcohort, suggest-
ing that these ﬁndings may be reliable. If so, it suggests the
involvement of MTNR1B in a complex glucose regulatory
feedback-loop or the presence of pleiotropic effects at this
locus, either of which would inform our understanding of
diabetes pathophysiology. MTNR1B encodes one of two
major receptors for the neurohormone melatonin (33) and
is expressed in several key tissues involved in regulation
of glucose homeostasis: the circadian rhythm control
center in the brain, hypothalamus, adipose tissue, liver,
kidney and the pancreatic -cells (9,34,35). Aspects of the
circadian rhythm (e.g., sleep-awake cycle, feeding and
hormone levels) are involved in the regulation of glucose
homeostasis. Some have hypothesized that effects of dis-
turbed sleep patterns on risk of metabolic disorders
(36,37) and decreased melatonin secretion might be inﬂu-
ence by MTNR1B variation (38). The recent ﬁnding that
MTNR1B is expressed in the  cells implies that the gene
variant might affect pancreatic glucose sensing and/or
insulin release and thereby glucose tolerance (9).
Elevations in glucose, whether deﬁned quantitatively or
categorically, are major predictors of type 2 diabetes and
cardiovascular disease, and studies that seek to determine
the genetic determinants of these traits may hence prove
informative for disease prevention. Therefore, the pro-
spective analyses presented here focused on the extent to
which the 16 glucose-raising gene variants predict changes
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is important to bear in mind that the longitudinal effects of
the risk alleles on worsening glucose control reported here
are for a follow-up period of 10 year. If the effects are
roughly linear throughout adulthood, the life-long impact
of these variants on glucose control is likely to be consid-
erably greater in magnitude. Thus, it may be possible to
identify persons at high genetic risk of developing diabetes
long before the manifestation of the clinical signs and
symptoms. The implication is that for these individuals,
early intervention might be beneﬁcial. Studies testing
prospective relationships with the development of diabe-
tes complications will be required to determine the clinical
value of these genetic prediction models and the potential
beneﬁts of early intervention. Unfortunately, such data are
presently unavailable in the GLACIER Study.
In the presence of detailed clinical and personal infor-
mation, the inclusion of genetic information statistically
improved the ability to predict IFG. However, the overall
predictive accuracy of these models is lower than reported
for diabetes incidence (25,26,39,40). This is unsurprising
given that, unlike frank diabetes, IFG is an intermediate
state of glucose dyshomeostasis, deﬁned by a relatively
narrow range of fasting glucose concentrations from
which people often regress; it may, thus, be that the
classiﬁcation of IFG is more prone to regression dilution
than the diagnosis of type 2 diabetes.
In conclusion, we have provided detailed replication of
many of the genetic effects report previously for fasting
and 2-h glucose concentrations (3). We extended previous
studies by identifying four loci (GCK, ADRA2A, DGKB-
TMEM195, and G6PC2) that may predict worsening glu-
cose control during 10 years of follow-up. Somewhat
paradoxically, the previously reported risk allele at
MTNR1B appears protective of worsening glucose toler-
ance during follow-up. Future studies testing prospective
relationships with glucose homeostasis, as well as with the
development of diabetes and its complications, will be
required to determine the clinical value of these genetic
prediction models. Although we were able to indentify
genetic determinants of hyperglycemia, it is likely that
lifestyle factors (e.g., diet, physical activity, and obesity)
play more pervasive roles in long-term glucose homeosta-
sis. Thus, studies that examine the interaction of these
genetic loci with lifestyle factors may facilitate the appli-
cation of genetic data to the prevention of type 2 diabetes
and its complications.
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